Abstract Library

#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study

Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Grana C

Authors: Grana C, Bertani E, Collamati F, Faccini R, Pisa E,

Keywords: Small intestine neuroendocrine tumors, liver metastases, β- probe, 90Y-DOTATOC,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus

Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Spada F, Pisa E, Lorizzo K, Barberis M, Fazio N,

Keywords: mTOR,